(Q48968494)

17 February 2018

title

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. (English)

1 reference

17 February 2018

0 references

3

Jeffrey Cummings

1 reference

17 February 2018

13

Clifford R Jack

1 reference

17 February 2018

15

Paul S Aisen

1 reference

17 February 2018

9

Adam Fleisher

1 reference

17 February 2018

Michael W. Weiner

12

Michael Weiner

1 reference

17 February 2018

Lon S Schneider

2

Lon S Schneider

1 reference

17 February 2018

Pierre N Tariot

1

Pierre N Tariot

1 reference

17 February 2018

Rema Raman

5

Rema Raman

1 reference

17 February 2018

Anton P Porsteinsson

11

Anton Porsteinsson

1 reference

17 February 2018

author name string

Ronald G Thomas

4

1 reference

17 February 2018

Laura J Jakimovich

6

1 reference

17 February 2018

Rebekah Loy

7

1 reference

17 February 2018

Barbara Bartocci

8

1 reference

17 February 2018

M Saleem Ismail

10

1 reference

17 February 2018

Leon Thal

14

1 reference

17 February 2018

Alzheimer's Disease Cooperative Study Group

16

1 reference

17 February 2018

language of work or name

English

0 references

publication date

1 August 2011

1 reference

17 February 2018

number of pages

9

1 reference

inferred from page(s)

published in

JAMA Psychiatry

1 reference

17 February 2018

volume

68

1 reference

17 February 2018

issue

8

1 reference

17 February 2018

page(s)

853-861

1 reference

17 February 2018

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

cites work

1 reference

12 December 2020

Longitudinal changes in behavioral problems in old age: a study in an adult day care population

1 reference

12 December 2020

The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

1 reference

12 December 2020

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition

1 reference

12 December 2020

Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing

1 reference

12 December 2020

Agitated behaviors in the elderly. I. A conceptual review

1 reference

12 December 2020

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial

1 reference

12 December 2020

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

1 reference

12 December 2020

Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

1 reference

12 December 2020

Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities.

1 reference

12 December 2020

The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS

1 reference

12 December 2020

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

12 December 2020

Clinical Dementia Rating (CDR).

1 reference

12 December 2020

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

1 reference

12 December 2020

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease

1 reference

12 December 2020

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

The course of psychopathologic features in mild to moderate Alzheimer disease.

1 reference

12 December 2020

Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study.

1 reference

12 December 2020

Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology

1 reference

12 December 2020

ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia

1 reference

12 December 2020

Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.

1 reference

12 December 2020

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

1 reference

12 December 2020

Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease.

1 reference

12 December 2020

Reversible altered consciousness with brain atrophy caused by valproic acid

1 reference

12 December 2020

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales

1 reference

12 December 2020

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

12 December 2020

Pseudoatrophy of the brain with valproic acid monotherapy.

1 reference

12 December 2020

Placebo-controlled study of divalproex sodium for agitation in dementia

1 reference

12 December 2020

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

12 December 2020

Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation.

1 reference

12 December 2020

Methodological considerations for measuring rates of brain atrophy

1 reference

12 December 2020

Functional communication with AD patients: a caregiver training program

1 reference

12 December 2020

Valproic acid-induced alterations in growth and neurotrophic factor gene expression in murine embryos [corrected]

1 reference

12 December 2020

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

12 December 2020

Longitudinal course of behavioral problems during Alzheimer's disease: linear versus curvilinear patterns of decline

1 reference

12 December 2020

Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models

1 reference

12 December 2020

Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease.

1 reference

12 December 2020

Psychotic symptoms and physically aggressive behavior in Alzheimer's disease.

1 reference

12 December 2020

Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.

1 reference

12 December 2020

10.1001/ARCHGENPSYCHIATRY.2011.72

Identifiers

DOI

1 reference

17 February 2018

0 references

1 reference

17 February 2018